France’s National Center for Scientific Research (CNRS) has announced the participation of Vect-Horus, a biotechnology company based in Marseille, France, at the Viva Technology conference in Paris from May 22-25, 2024.
Vect-Horus specializes in designing molecular vectors that aid in the targeted delivery of therapeutic molecules and imaging agents to organs and tumors. They have been chosen to present their VECTrans® technology at the event, which is a unique breakthrough in drug targeting for the brain and other pathological tissues such as cancers.
Jean-Manuel Pean, the Chief Scientific Officer of Vect-Horus, will be part of a roundtable discussion where he will provide an overview of the Company and its pipeline. He will discuss the progress made with the VECTrans® technology, the early clinical trials of their theragnostic agent for glioblastoma and pancreatic cancer, and provide updates on their partnerships with Novo Nordisk and Ionis Pharmaceuticals.
Founded in 2005 as a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), Vect-Horus focuses on developing vectors for targeting and delivering therapeutic or imaging agents to organs and tumors. With 38 employees, predominantly in research and development, they continue to make strides in the biotechnology field. For more information about Vect-Horus visit www.vect-horus.com or contact them at contact@vect-horus.com or reach out to their Business Development and Alliance Manager Emmanuelle Bettendorf or media relations team at Cohesion Bureau for media inquiries or press releases.